Navigation Links
Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
Date:6/27/2012

ncluding a SELENA/SLEDAI** improvement of 5 points or greater, no increase in a physician's global assessment of more than 0.3 points, with no new BILAG A or two or more new BILAG B organ domain scores.

About Blisibimod and PEARL-SCBAFF has been associated with a wide range of B-cell-mediated autoimmune diseases, including systemic lupus erythematosus, vasculitis, IgA nephropathy, immune thrombocytopenic purpura and others. Multiple clinical studies with other BAFF antagonists recently have reported on BAFF's potential positive role in treating lupus and rheumatoid arthritis. Anthera is advancing its development of blisibimod, a broad inhibitor of BAFF, to expand its potential clinical utility in autoimmune diseases. Blisibimod is a novel fusion protein called a peptibody and is distinct from an antibody. Anthera owns worldwide rights to blisibimod in all potential indications.  The PEARL-SC Phase 2 study was designed as a randomized, double-blind, placebo-controlled, dose-ranging superiority trial to evaluate the safety, tolerability and efficacy of blisibimod plus standard of care, versus placebo plus standard of care.  A total of 547 patients with active SLE were randomized to receive one of three different doses of blisibimod or placebo (100 mg weekly, 200 mg weekly or 200 mg monthly) administered subcutaneously over a minimum 24-week treatment period, in addition to standard-of-care therapy. The study was conducted at multiple centers worldwide.About Anthera PharmaceuticalsAnthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan,
'/>"/>

SOURCE Anthera Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
2. Anthera Announces First Quarter 2012 Financial Report and Conference Call
3. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
4. Neuralstem Updates ALS Stem Cell Trial Progress
5. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
6. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
7. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
8. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
9. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
10. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Foundation today announced it has established a relief fund ... weather that has gripped much of the nation. AARP and ... to support these emergency relief efforts AARP and AARP Foundation ... up to $500,000 in aid. The matching program will be ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces that ... to the announced tender offer for all of the outstanding shares ... of the waiver, the transaction is no longer conditional on OFT ... 24, 2014 following the currently scheduled expiration time, subject to the ...
(Date:1/15/2014)... an unprecedented effort to curb the spread of "superbugs" such as ... an advanced and portable UV germicidal lamp manufactured by MRSA-UV is ... In order to prevent EMS paramedics and transport patients ... Palm Beach Fire Rescue is the first in the ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2
(Date:4/24/2014)... Oregon State University researcher has found a relationship between ... of autism spectrum disorder in very young children. ... to show a direct relationship between motor skills and ... motor skills should be included in treatment plans for ... professor in OSU,s College of Public Health and Human ...
(Date:4/24/2014)... New research led by a scientist at the University ... key element in the development of the nervous system ... of breast cancer., A research team, led by ... the Department of Biology at York, has studied how ... tumours. These channels are found in the membranes of ...
(Date:4/23/2014)... Pregnant immigrants from Sub-Saharan Africa, Latin America ... pregnancy, according to new research from St. Michael,s ... British Journal of Obstetrics and Gynaecology , ... among immigrants and native-born women in six high-immigration ... Spain (Catalonia and Valencia) and the United States ...
(Date:4/23/2014)... at the National Institute of Arthritis and Musculoskeletal and ... of the Ross Prize in Molecular Medicine, conferred by ... . The award will be given on June 9 ... followed by scientific presentations by Dr. O,Shea and other ... of Health. , The award, which includes a $50,000 ...
(Date:4/23/2014)... that rats exposed to high-energy particles, simulating conditions astronauts ... lapses in attention and slower reaction times, even when ... , The cognitive impairments which affected a large ... appear to be linked to protein changes in the ... hold true in humans, suggest it may be possible ...
Breaking Medicine News(10 mins):Health News:Motor skill deficiencies linked to autism severity in new research 2Health News:Breast cancer replicates brain development process 2Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3
... international body of knowledge to Texas,research center in ... The University of,North Texas Health Science Center ... recently added several new members to its faculty,to ... and,osteopathic manipulative medicine., Anuja Ghorpade has joined ...
... WALTHAM, Mass., Nov. 21 Inverness Medical,Innovations, Inc. (Amex: ... announced public offering on Tuesday. The Company sold a ... offering price of $61.49,per share. The total number of ... the underwriters upon their exercise of their,over-allotment option in ...
... 30,000 Clinic Locations, WASHINGTON, Nov. 21 ... announced the week after Thanksgiving,November 27 to December ... recommendations, influenza vaccination (flu shot) rates in young,children ... age 6 to 23,months were fully immunized for ...
... ATLANTA, Nov. 21 Eclipsys Corporation(R),(Nasdaq: ECLP ... be,participating in the Merrill Lynch Health Services Investor ... (Logo: http://www.newscom.com/cgi-bin/prnh/20050209/FLW006LOGO ), Eclipsys ... 28th at 10:00 a.m. Eastern time. Interested parties ...
... Czymmek, as he points to the video on his computer ... fireworks flash across the screen with every pulsation of the ... there is a large release of calcium with every heartbeat. ... a major problem--perhaps even heart failure. , Czymmek has a ...
... Nov. 21 Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ... Development (R&D),Day on Wednesday, November 28, 2007 at ... New York., "Amylin is focused on bringing ... our sustainable approach to the,discovery and development of ...
Cached Medicine News:Health News:UNT Health Science Center Appoints Eight New Faculty Members 2Health News:UNT Health Science Center Appoints Eight New Faculty Members 3Health News:Inverness Medical Innovations Announces Closing of Public Offering 2Health News:Asthma Foundation Offers National Flu Shot Finder 2Health News:Eclipsys to Present at the Merrill Lynch Health Services Investor Conference 2Health News:Eclipsys to Present at the Merrill Lynch Health Services Investor Conference 3Health News:New microscope peers into secret lives of cells 2Health News:New microscope peers into secret lives of cells 3Health News:Amylin Pharmaceuticals to Present at Research & Development Day 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: